CAMBRIDGE, Mass., Feb. 6 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the election of Anthony H. Wild, Ph.D., to the Millennium Board of Directors. Dr. Wild, chairman and chief executive officer of MedPointe Pharmaceuticals, has 30 years of pharmaceutical industry experience including executive positions with Warner- Lambert (now part of Pfizer Inc) and Schering-Plough Corporation.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
“We are very pleased to welcome Dr. Wild to the Millennium Board,” said Deborah Dunsire, M.D., president and chief executive officer of Millennium. “We believe that his experience in managing multi-billion dollar commercial operations, major research and development organizations and key business acquisitions will enable him to make significant contributions to the Company’s sustained growth and ability to deliver innovative medicines to patients.”
Prior to joining MedPointe Pharmaceuticals, Dr. Wild served as executive vice president of Warner-Lambert and president of its pharmaceutical sector. During his tenure, he had worldwide responsibility for the pharmaceutical commercial operations and research and development. Under his leadership, Warner-Lambert’s pharmaceutical sector grew from $2.1 billion in sales with 14,000 employees in 1995 to an estimated $9.5 billion in 2000 with 21,000 employees. During this period, Dr. Wild oversaw a number of key transactions including the Pfizer global Lipitor(R) co-marketing partnership.
“This is an exciting time to be a part of the Company’s success as Millennium strengthens its commercial presence and accelerates the development of a rich product pipeline,” said Dr. Wild. “I look forward to working together with the Board to enhance the Company’s growth and increase shareholder value.”
Before joining Warner-Lambert, Dr. Wild spent 22 years with Schering- Plough Corporation in a number of positions across the globe, culminating as president of Schering-Plough’s Japanese operations, a $500 million business. Dr. Wild also served at Sandoz AG as a development chemist, where he worked on optimization and simulation of chemical processes.
Dr. Wild is a member of the Board of Advisors to the Joseph L. Mailman School of Public Health at Columbia University, a Trustee of the Healthcare Institute of New Jersey, past Chairman of the International Section of Pharmaceutical Research and Manufacturers of America and past Governor of the American Chamber of Commerce in Japan.
Dr. Wild graduated from the University of York with a B.A. honors degree in Chemistry and received a Ph.D. in Physical Chemistry from the University of Cambridge.
Dr. Wild’s appointment brings the number of directors on the Millennium Board to ten.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical Company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company’s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is seeking to develop breakthrough products. The Company’s website is http://www.millennium.com.
This press release contains “forward-looking statements,” including statements about the Company’s growth, discovery and development of products and shareholder value. Various important risks may cause the Company’s actual results to differ materially from the results indicated by these forward- looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company’s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company’s products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Lipitor(R) is a registered trademark of Pfizer Inc.
Editor’s Note: This release is available on the Media section of the Millennium website at http://www.millennium.com
Contact:
Theresa McNeely (media) Kyle Kuvalanka (investors) (617) 679-7405 (617) 761-4734
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comMillennium Pharmaceuticals, Inc.
CONTACT: Theresa McNeely, Media Contact, +1-617-679-7405, or KyleKuvalanka, Investors Contact, +1-617-761-4734, both of MillenniumPharmaceuticals, Inc.
Web site: http://www.millennium.com//
Company News On-Call: http://www.prnewswire.com/comp/114562.html/
